Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.

Chromocell Therapeutics Corporation

Chromocell is a life sciences company which improves consumer products and patient lives through breakthrough science and technologies. Chromocell is focused on the discovery and development of therapeutics and flavors through the use of pioneering Chromovert® technology. Chromovert technology enables Chromocell to use rare cells ideally suited for effective high-throughput screening. Chromocell’s therapeutics pipeline is currently focused on analgesics and rare diseases, where Chromovert technology has proven highly effective in the rapid identification of potential new drug candidates. In our flavors and nutrition business, Chromocell works with global consumer goods companies to discover and develop flavor ingredients and natural taste enhancers. The technology is applicable to all areas of taste sensations as well as aroma and fragrance enhancer discovery.

	Dec '21	Dec '22	Dec '23
account payables	2.58M -	2.99M 16.03%	4.62M 54.34%
accumulated other comprehensive income loss		-10.00K -	-391 96.09%
cash and cash equivalents		55.07K -	96.39K 75.02%
cash and short term investments		55.07K -	96.39K 75.02%
common stock		10K -	391 96.09%
deferred revenue		1 -
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt	1.10M -
long term investments
net debt	1.10M -	485.36K 55.87%	1.17M 141.53%
net receivables
other assets
other current assets
other current liabilities		227.26K -	651.33K 186.60%
other liabilities
other non current assets
other non current liabilities
othertotal stockholders equity		2.43M -	7.07M 190.93%
preferred stock		600 -	60 90%
property plant equipment net
retained earnings	-3.68M -	-6.14M 66.80%	-13.52M 120.23%
short term debt		540.43K -	1.27M 134.75%
short term investments
tax assets
tax payables
total assets		55.07K -	96.39K 75.02%
total current assets		55.07K -	96.39K 75.02%
total current liabilities	2.58M -	3.76M 45.78%	6.54M 73.89%
total debt	1.10M -	540.43K 50.87%	1.27M 134.75%
total investments
total liabilities	3.68M -	3.76M 2.21%	6.54M 73.89%
total liabilities and stockholders equity		55.07K -	96.39K 75.02%
total non current assets
total non current liabilities	1.10M -
total stockholders equity	-3.68M -	-3.71M 0.71%	-6.44M 73.87%

COM:CHROMOCELL

Chromocell

Last Close

0.63

22/11 20:59

Market Cap

3.88M

Beta: -

Volume Today

84.03K

Avg: -

Preview